LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Heron Therapeutics Inc

Închisă

SectorSănătate

1.1 -0.9

Rezumat

Modificarea prețului

24h

Curent

Minim

1.1

Maxim

1.1

Indicatori cheie

By Trading Economics

Venit

-15M

-17M

Vânzări

1M

38M

EPS

-0.036

Marjă de profit

-45.783

Angajați

122

EBITDA

-1.8M

-3.5M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+309.09% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-13M

204M

Deschiderea anterioară

2

Închiderea anterioară

1.1

Sentimentul știrilor

By Acuity

67%

33%

312 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Heron Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 nov. 2025, 17:45 UTC

Câștiguri
Principalele dinamici ale pieței

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov. 2025, 17:31 UTC

Câștiguri
Principalele dinamici ale pieței

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16 nov. 2025, 23:40 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

16 nov. 2025, 23:36 UTC

Market Talk

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16 nov. 2025, 23:26 UTC

Market Talk

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16 nov. 2025, 16:20 UTC

Câștiguri

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15 nov. 2025, 09:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

15 nov. 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15 nov. 2025, 00:08 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov. 2025, 23:56 UTC

Achiziții, Fuziuni, Preluări

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov. 2025, 22:35 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov. 2025, 22:32 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov. 2025, 22:29 UTC

Câștiguri

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov. 2025, 22:00 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

14 nov. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov. 2025, 20:17 UTC

Achiziții, Fuziuni, Preluări

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov. 2025, 19:29 UTC

Market Talk
Câștiguri

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov. 2025, 18:44 UTC

Market Talk
Câștiguri

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov. 2025, 17:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

14 nov. 2025, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

14 nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Comparație

Modificare preț

Heron Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

309.09% sus

Prognoză pe 12 luni

Medie 4.5 USD  309.09%

Maxim 6 USD

Minim 3 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHeron Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.0001 / 2.42Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

312 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat